Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16058118 | 0.81 | ADORA1 (0.42) | PDE4BKDM4EADORA1USP2ALDH1A1 | |
| SCHEMBL6288151 | 0.79 | KDM4E (0.40) | KDM4EMAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL12499191 | 0.79 | PDE4B (0.42) | PDE4BKDM4EMAPTKMT2AMEN1 | |
| SCHEMBL12499855 | 0.78 | KDM4E (0.44) | PDE4BKDM4EMAPTKMT2AMEN1 | |
| SCHEMBL16059052 | 0.78 | KMT2A (0.36) | PDE4BKDM4EMAPTKMT2AADORA1 | |
| SCHEMBL8229160 | 0.74 | PDE4B (0.42) | PDE4BKDM4EMAPTKMT2AMEN1 | |
| SCHEMBL12498714 | 0.69 | KDM4E (0.58) | KDM4EKMT2A | |
| SCHEMBL12684379 | 0.68 | EZH2 (0.46) | PDE4BKDM4EMAPTKMT2AMEN1 | |
| SCHEMBL1436080 | 0.67 | MEN1 (0.45) | PDE4BMAPTKMT2AMEN1GMNN | |
| SCHEMBL19391703 | 0.66 | KDM4E (0.43) | PDE4BKDM4EMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3323820-B1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | EPIZYME INC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20200317643-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2020-10-08 | — | — | US | disclosed |
| US-20190300502-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2019-10-03 | — | — | US | disclosed |
| US-10273223-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180072702-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180072702-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2018-03-15 | — | — | US | disclosed |
| EP-2681216-B1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | EPIZYME INC (US) | 2017-09-27 | — | — | EP | disclosed |
| US-9637472-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637472-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9206157-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150266854-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. | 2015-09-24 | — | — | US | disclosed |
| US-20150065483-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. | 2015-03-05 | — | — | US | disclosed |
| US-20150065483-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. | 2015-03-05 | — | — | US | disclosed |
| US-8962620-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962620-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140057891-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057891-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. (US) | 2014-02-27 | — | — | US | disclosed |
| EP-2681216-A2 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012118812-A2 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2012-09-07 | — | — | WO | disclosed |
| WO-2012118812-A2 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2012-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.